Intravenous Vitamin C Administration Improved Blood Cell Counts and Health-Related Quality of Life of Patient with History of Relapsed Acute Myeloid Leukaemia.
Mike N FosterAnitra C. CarrAlina AntonySelene PengMike G FitzpatrickPublished in: Antioxidants (Basel, Switzerland) (2018)
A 52-year-old female presented to Integrated Health Options Clinic in October 2014 with a history of relapsed acute myeloid leukaemia (AML, diagnosed in 2009 and relapsed in 2014). Intravenous(IV) vitamin C therapy was initiated (in 2014) following completion of chemotherapy as an alternative to haematopoietic stem cell transplantation. IV vitamin C was administered twice weekly at a dose of 70 g/infusion. Within 4 weeks of initiation of IV vitamin C therapy, there was a dramatic improvement in the patient's blood indices with platelet cell counts increasing from 25 × 10⁸/L to 196 × 10⁸/L and white blood cell counts increasing from 0.29 × 10⁸/L to 4.0 × 10⁸/L, with further improvements observed over the next 18 months. Furthermore, there was a clear and sustained improvement in the patient's health-related quality of life scores assessed using a validated questionnaire. She has remained healthy and in complete remission until the present day. This case study highlights the benefits of IV vitamin C as a supportive therapy for previously relapsed AML.
Keyphrases
- acute myeloid leukemia
- acute lymphoblastic leukemia
- stem cell transplantation
- high dose
- single cell
- multiple myeloma
- diffuse large b cell lymphoma
- cell therapy
- hodgkin lymphoma
- case report
- liver failure
- healthcare
- bone marrow
- dendritic cells
- public health
- low dose
- respiratory failure
- primary care
- intensive care unit
- squamous cell carcinoma
- locally advanced
- rheumatoid arthritis
- mesenchymal stem cells
- immune response
- social media
- acute respiratory distress syndrome